Man looking on a tablet and Onconova Therapeutics logo
Source: istock, Onconova Therapeutics Twitter

Why Onconova Therapeutics (ONTX) Stock Is a Speculative Bet

By

Mar. 18 2021, Published 8:19 a.m. ET

Biotech company Onconova Therapeutics (ONTX) rose almost 15 percent on March 17 and is now up 164 percent for the year. Why is ONTX stock rising? Also, is ONTX a good stock to buy at the current levels?

Article continues below advertisement

Onconova Therapeutics is a clinical-stage biopharma company that's focused on developing products for cancer care. It isn't uncommon for clinical-stage pharma companies to witness high volatility especially around the time when they announce trial results.

onconova therapeutics stock
Source: Onconova Therapeutics Facebook
Article continues below advertisement

Onconova Therapeutics' news

On March 11, Onconova Therapeutics released its 2020 earnings and provided a business update. The company said that its proprietary multi-kinase inhibitor ON 123300 has received FDA clearance to begin Phase 1 studies. It has also received approval from an Institutional Review Board at one U.S. clinical trial site.

In February, the company closed a stock offering of $28.75 million. Clinical stage companies like Onconova burn a lot of cash during the trial phase even when they make negligible revenues over the period.

Article continues below advertisement

WallStreetBets and Reddit on ONTX stock

While Reddit groups, especially WallStreetBets, have pumped many stocks in 2021, that doesn't seem to be the case with Onconova Therapeutics. There isn't much discussion about ONTX stock on WallStreetBets or other Reddit groups.

ONTX stock on Stocktwits

Many Stocktwits users are discussing ONTX stock. Username monour56 expects the stock to hit $1.5 by the end of this week and $2 by the end of the month. The stock closed at $1.23 on March 17. Another user going by the username HARRRRRRY also sees massive upside potential in the stock.

Article continues below advertisement
onconova therapeutics stock forecast
Source: Unsplash

ONTX's stock forecast

ONTX is a penny stock and was on the verge of getting delisted. Its stock price was too low for the listing requirements. Not many analysts cover penny stocks. According to the estimates compiled by CNN Business, only two analysts cover ONTX stock.

Article continues below advertisement

One analyst has a buy rating, while the other rates ONTX as a hold or some equivalent. Only one analyst has given the target price of $2.10 to ONTX, which is a premium of 73 percent over the current prices.

Article continues below advertisement

ONTX stock is a risky investment.

ONTX stock has been rising amid optimism about ON 123300. The company is participating in three conferences this month. Usually, clinical-stage companies provide updates on the product that they are developing during these conferences.

Two of these conferences, the H.C. Wainwright Global Life Sciences Virtual Conference and the Virtual 33rd Annual Roth Conference, have already concluded. The Maxim Group Emerging Growth Virtual Conference will conclude on March 18. It looks unlikely that the company will have something new to share with investors after back-to-back conferences.

Article continues below advertisement

While the demand for cancer care is expected to be strong amid rising cases globally, ONTX will remain a speculative bet as long as it's in the clinical trial stage. However, as the adage goes, those who take the highest risk end up getting the highest returns (at least in theory).

onconova therapeutics ontx stock price
Source: TIKR

ONTX stock price chart versus moving averages

Article continues below advertisement

It, however, holds in clinical-stage pharma companies as the stocks skyrocket after the product is commercialized. However, there is always the risk of the product not seeing the light of the day.

Outlook for Onconova Therapeutics stock

There isn't a near-term catalyst for Onconova Therapeutics stock after the investor conferences. Given the sharp rise in the stock this month, it looks susceptible to a fall. I wouldn't buy the stock at these prices.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.